Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
|
|
Iterum Therapeutics plc (ITRM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/11/2023 |
8-K
| Quarterly results|
Docs:
|
"ITERUM THERAPEUTICS PLC Condensed Consolidated Statement of Operations Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Operating expenses: Research and development General and administrative Total operating expenses Operating loss Interest expense, net Adjustments to fair value of derivatives 2,155 7,332 Other income, net 50 269 91 431 Income tax expense Net loss $ $ $ $ Net loss per share – basic and diluted $ $ $ $ Weighted average ordinary shares outstanding – basic and diluted 12,942,969 12,224,324 12,812,398 12,208,961 Reconciliation of non-GAAP net loss to GAAP net loss Net loss - GAAP $ $ $ $ Intangible asset amortization 429 429 858 858 Share based compensation 110 1,984 503 3,879 Interest expense - accrued interest and amortization on Exchang..." |
|
| 08/01/2023 |
8-K
| Quarterly results |
| 07/13/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/06/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/06/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/03/2023 |
4
| Dunne Michael W. (Director) has filed a Form 4 on Iterum Therapeutics plc|
Txns:
| Exercised 1,779 options to buy
@ $0 |
|
| 07/03/2023 |
4
| HUNT RONALD (Director) has filed a Form 4 on Iterum Therapeutics plc|
Txns:
| Exercised 2,796 options to buy
@ $0 |
|
| 06/15/2023 |
4
| Hecht Beth (Director) has filed a Form 4 on Iterum Therapeutics plc|
Txns:
| Exercised 15,853 options to buy
@ $0 |
|
| 06/15/2023 |
4
| Dunne Michael W. (Director) has filed a Form 4 on Iterum Therapeutics plc|
Txns:
| Exercised 15,853 options to buy
@ $0 |
|
| 06/15/2023 |
4
| Chin Mark (Director) has filed a Form 4 on Iterum Therapeutics plc|
Txns:
| Exercised 15,853 options to buy
@ $0 |
|
| 06/12/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 06/12/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/12/2023 |
8-K
| Quarterly results |
| 05/04/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
| 04/13/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/03/2023 |
4
| HUNT RONALD (Director) has filed a Form 4 on Iterum Therapeutics plc|
Txns:
| Exercised 2,041 options to buy
@ $0 |
|
| 04/03/2023 |
4
| Matthews Judith M. (CFO) has filed a Form 4 on Iterum Therapeutics plc|
Txns:
| Granted 100,000 options to buy
@ $1, valued at
$100k
|
|
| 04/03/2023 |
4
| Puttagunta Sailaja (Chief Medical Officer) has filed a Form 4 on Iterum Therapeutics plc|
Txns:
| Granted 75,000 options to buy
@ $1, valued at
$75k
|
|
| 04/03/2023 |
4
| Dunne Michael W. (Director) has filed a Form 4 on Iterum Therapeutics plc|
Txns:
| Exercised 1,299 options to buy
@ $0 |
|
| 04/03/2023 |
4
| Fishman Corey N. (CEO) has filed a Form 4 on Iterum Therapeutics plc|
Txns:
| Granted 275,000 options to buy
@ $1, valued at
$275k
|
|
| 03/16/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/16/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/16/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/16/2023 |
8-K
| Quarterly results|
Docs:
|
"ITERUM THERAPEUTICS PLC Condensed Consolidated Statement of Operations For the three months ended December 31, Year ended December 31, 2022 2021 2022 2021 Operating expenses: Research and development General and administrative Total operating expenses Operating loss Interest income / , net 80 Adjustments to fair value of derivatives 2,960 3,562 5,458 Cancellation of share options - - - Other income, net 28 503 195 Income tax expense Net loss attributable to ordinary shareholders $ $ $ $ Net loss per share attributable to ordinary shareholders – basic and diluted $ $ $ $ Weighted average ordinary shares outstanding – basic and diluted 12,294,865 12,185,019 12,236,607 10,891,178 Reconciliation of non-GAAP net loss to GAAP net loss Net loss - GAAP $ $ $ $ Intangible asset amortiza..." |
|
| 03/14/2023 |
4
| Matthews Judith M. (CFO) has filed a Form 4 on Iterum Therapeutics plc|
Txns:
| Granted 6,666 shares
@ $0
Paid exercise price by delivering 2,883 shares
@ $0.96, valued at
$2.8k
Exercised 6,666 options to buy
@ $0 |
|
| 03/14/2023 |
4
| Fishman Corey N. (CEO) has filed a Form 4 on Iterum Therapeutics plc|
Txns:
| Granted 14,333 shares
@ $0
Paid exercise price by delivering 5,683 shares
@ $0.96, valued at
$5.5k
Exercised 14,333 options to buy
@ $0 |
|
| 03/06/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 02/27/2023 |
4/A
| Dunne Michael W. (Director) has filed a Form 4 on Iterum Therapeutics plc |
| 01/04/2023 |
4
| Dunne Michael W. (Director) has filed a Form 4 on Iterum Therapeutics plc|
Txns:
| Exercised 761 options to buy
@ $0 |
|
| 01/04/2023 |
4
| HUNT RONALD (Director) has filed a Form 4 on Iterum Therapeutics plc|
Txns:
| Exercised 1,197 options to buy
@ $0 |
|
|
|
|